Jeanene Swanson

Blog Post

FDA Approves Jacobus Pharmaceuticals’ Ruzurgi for Treatment of Children with Lambert-Eaton Myasthenic Syndrome

By Jeanene Swanson | May 8, 2019
Blog Post

Mouse Study Finds Link Between Key Mitochondrial Protein and CMT2A, Making It a Possible Therapeutic Target

By Jeanene Swanson | May 1, 2019
Blog Post

MDA Partners with the Broad Institute on Rare Genomes Project for Limb-Girdle Muscular Dystrophy

By Jeanene Swanson | April 12, 2019
Blog Post

Audentes Therapeutics Announces Plans to Develop Gene-Targeted Therapies for Duchenne Muscular Dystrophy and Myotonic Dystrophy Type 1

By Jeanene Swanson | April 11, 2019
Blog Post

Muscular Dystrophy Association Awards Eight Grants Totaling More Than $2 Million for ALS Research

By Jeanene Swanson | April 8, 2019
Blog Post

Sarepta Therapeutics Announces Positive Interim Results from Study of Casimersen to Treat DMD Amenable to Exon 45 Skipping

By Jeanene Swanson | April 4, 2019
Blog Post

FDA Grants Orphan Drug Designation to Acceleron Pharma’s ACE-083 Muscle Growth Drug for Charcot-Marie-Tooth Disease

By Jeanene Swanson | April 3, 2019
Blog Post

Sarepta Therapeutics Announces Positive Interim Results in Gene Therapy Trial for LGMD2E and Acquisition of Myonexus Therapeutics

By Jeanene Swanson | March 15, 2019
Blog Post

FDA Grants Breakthrough Therapy Designation to Amicus’ Experimental Therapy, AT-GAA, for Late-Onset Pompe Disease

By Jeanene Swanson | March 7, 2019
Blog Post

CMTA and MDA Co-Fund Proof-of-Concept Study Using AAV Vector to Deliver Gene Replacement Therapy in X-linked Charcot-Marie-Tooth Disease

By Jeanene Swanson | March 1, 2019